After the approval of the first bispecific antibody for myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom’s public body for medicine appraisals) approved today, 16 July 2024, a second bispecific drug, teclistamab. Commercially known as Tecvayli® and marketed by Janssen, the drug has been approved for people at fourth line and beyond, with a few further restrictions.

Please click here to read more about this approval in England and Wales and the efforts of Myeloma UK to push for wider patient access.

To find out more about teclistamab please see MPE’s factsheet on this drug here.